Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy
- 1 July 1994
- journal article
- research article
- Published by Springer Nature in Intensive Care Medicine
- Vol. 20 (3) , S43-S48
- https://doi.org/10.1007/bf01745251
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Aspiration PneumoniaClinical Infectious Diseases, 1991
- Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1991
- New and Emerging Etiologies for Community-Acquired Pneumonia with Implications for TherapyMedicine, 1990
- In vitro Effect of YTR (Tazobactam) on Plasmid and Chromosomally Mediated β-LactamasesChemotherapy, 1990
- Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830)Diagnostic Microbiology and Infectious Disease, 1989
- Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanateAntimicrobial Agents and Chemotherapy, 1989
- Induction/Inhibition of Chromosomal β-Lactamases by β-Lactamase InhibitorsClinical Infectious Diseases, 1986
- Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillinAntimicrobial Agents and Chemotherapy, 1984
- Penetration of piperacillin into bronchial mucosa and sputum.Thorax, 1981
- Clavulanic Acid, a Novel Inhibitor of β-LactamasesAntimicrobial Agents and Chemotherapy, 1978